Cabaletta Bio to Participate in Upcoming Investor Conferences in December

Rhea-AI Summary

Cabaletta Bio (Nasdaq: CABA) has announced its participation in two major investor conferences this December. The company will present a fireside chat at the 7th Annual Evercore HealthCONx Conference on December 4, 2024, at 7:55 a.m. ET in Coral Gables, FL. On the same day, management will be available for one-on-one meetings at Citi's 2024 Global Healthcare Conference in Miami, FL.

The fireside chat will be webcast live and accessible through Cabaletta's website, with replays available for 30 days. The company specializes in developing curative targeted cell therapies for autoimmune diseases.

News Market Reaction

+5.68%

1 alert

+5.68% News Effect

On the day this news was published, CABA gained 5.68%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

PHILADELPHIA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in the following investor conferences in December:

• 7th Annual Evercore HealthCONx Conference: Fireside chat on Wednesday, December 4, 2024, at 7:55 a.m. ET in Coral Gables, FL. Members of management will also be available for one-on-one meetings.
  
  
• Citi’s 2024 Global Healthcare Conference: Members of management will be available for one-on-one meetings on Wednesday, December 4, 2024, in Miami, FL.
  

A live webcast of the fireside chat will be available on the News and Events section of the Company’s website at www.cabalettabio.com. Replays will be available on the website for 30 days.

About Cabaletta Bio
Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases. The CABA™ platform encompasses two complementary strategies which aim to advance the discovery and development of engineered T cell therapies with the potential to become deep and durable, perhaps curative, treatments for a broad range of autoimmune diseases. The lead CARTA (Chimeric Antigen Receptor T cells for Autoimmunity) strategy is prioritizing the development of CABA-201, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy. CABA-201 is currently being evaluated in the RESET™ (REstoring SElf-Tolerance) clinical development program spanning multiple therapeutic areas, including rheumatology, neurology and dermatology. Cabaletta Bio’s headquarters and labs are located in Philadelphia, PA. For more information, please visit www.cabalettabio.com and connect with us on LinkedIn.

Contacts:

Anup Marda
Chief Financial Officer
investors@cabalettabio.com

William Gramig
Precision AQ
william.gramig@precisionaq.com

FAQ

When is Cabaletta Bio (CABA) presenting at the Evercore HealthCONx Conference?

Cabaletta Bio will present a fireside chat on Wednesday, December 4, 2024, at 7:55 a.m. ET in Coral Gables, FL.

Which investor conferences is Cabaletta Bio (CABA) attending in December 2024?

Cabaletta Bio is attending the 7th Annual Evercore HealthCONx Conference and Citi's 2024 Global Healthcare Conference, both on December 4, 2024.

Where can investors watch Cabaletta Bio's (CABA) December 2024 fireside chat?

Investors can watch the fireside chat live webcast on Cabaletta Bio's website (www.cabalettabio.com) in the News and Events section, with replays available for 30 days.